UroNurse Episode 116: Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Recent advances in prostate cancer screening have addressed the limitations of prostate-specific antigen (PSA) testing, which has a lack of specificity and a risk of overdiagnosis and overtreatment. New biomarker tests offer greater diagnostic accuracy by targeting specific biomarkers and potentially reducing unnecessary biopsies.

This educational activity aims to update health care professionals on advances in prostate cancer screening with the goal of improving prostate cancer risk assessment and decision-making and reducing unnecessary treatments. The Medical Crossfire format facilitates discussion in the context of evidence-based presentations, highlighting the current challenges and opportunities in the field and providing practical advice for implementing best practices.